Description

Arbivir (Umifenovir) Coated Tablets 50 mg. №20

Ingredients

Active ingredient: Umifenovir 50 mg.
Other ingredients: Microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, hypromellose, macrogol, titanium dioxide, talc.

Dosage

Recommended dosage: 1 tablet orally three times a day.
Do not exceed the recommended dose without medical advice.

Indications

Arbivir (Umifenovir) Coated Tablets are indicated for the treatment and prophylaxis of influenza and other respiratory viral infections.

Contraindications

Do not use Arbivir (Umifenovir) Coated Tablets if you are allergic to umifenovir or any other ingredients in the product.
Consult a healthcare provider before use if you are pregnant, breastfeeding, or have any underlying medical conditions.

Directions

Take Arbivir (Umifenovir) Coated Tablets as directed by your healthcare provider.
Swallow the tablet whole with a glass of water.
Do not crush or chew the tablet.

Scientific Evidence

Umifenovir, the active ingredient in Arbivir tablets, has shown promising antiviral activity against a wide range of respiratory viruses. Studies have demonstrated its ability to inhibit viral replication and enhance the host immune response. Research suggests that umifenovir may be effective in reducing the severity and duration of influenza symptoms.

Additional Information

It is important to complete the full course of treatment with Arbivir (Umifenovir) Coated Tablets as prescribed, even if symptoms improve before the course is finished.
Store the tablets in a cool, dry place away from direct sunlight.
Keep out of reach of children.

Pharmacological Effects: Umifenovir works by blocking viral entry into host cells and stimulating the immune system’s response to viral infections. This dual mechanism of action makes it a valuable agent in the management of respiratory viral illnesses.

Clinical Trials: Clinical trials have shown that Arbivir (Umifenovir) Coated Tablets are well-tolerated and effective in reducing the duration of symptoms associated with influenza and other respiratory viral infections. Patients treated with umifenovir have shown faster recovery times and lower rates of complications compared to placebo groups.